Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-a (IFN) Refractoriness/Intolerance.

被引：0
|
作者：
Kantarjian, Hagop M.
Sawyers, Charles
Hochhaus, Andreas
Schiffer, Charles A.
Guilhot, Francois
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Fischer, Thomas
Goldman, John
Krahnke, T.
Mone, M.
Talpaz, Moshe
Druker, Brian J.
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Karmanos Canc Inst, Detroit, MI USA
[5] CHU La Miletrie, Poitiers, France
[6] Univ Leipzig, D-7010 Leipzig, Germany
[7] Inst Natl Tumori, Milan, Italy
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Univ Mainz, D-6500 Mainz, Germany
[10] NHLBI, Bethesda, MD 20892 USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
428
引用
收藏
页码：130A / 131A
页数：2
相关论文
共 50 条
  • [21] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    Giles, F. J.
    le Coutre, P. D.
    Pinilla-Ibarz, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Hochhaus, A.
    Radich, J. P.
    Saglio, G.
    Hughes, T. P.
    Martinelli, G.
    Kim, D-W
    Novick, S.
    Gillis, K.
    Fan, X.
    Cortes, J.
    Baccarani, M.
    Kantarjian, H. M.
    LEUKEMIA, 2013, 27 (01) : 107 - 112
  • [22] Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
    F J Giles
    P D le Coutre
    J Pinilla-Ibarz
    R A Larson
    N Gattermann
    O G Ottmann
    A Hochhaus
    J P Radich
    G Saglio
    T P Hughes
    G Martinelli
    D-W Kim
    S Novick
    K Gillis
    X Fan
    J Cortes
    M Baccarani
    H M Kantarjian
    Leukemia, 2013, 27 : 107 - 112
  • [23] Long-term follow-up results of alpha-interferon (alpha-IFN)-based regimens in patients with late chronic phase chronic myelogenous leukemia (CP-CML).
    Sacchi, S
    Kantarjian, H
    OBrien, S
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1996, 88 (10) : 3531 - 3531
  • [24] Long-Term Follow-up of a Phase 1 Study of Ponatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Talpaz, Moshe
    Cortes, Jorge E.
    Kantarjian, Hagop
    Shah, Neil P.
    Bixby, Dale
    Flinn, Ian
    O'Hare, Thomas
    Hu, Simin
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Deininger, Michael W.
    Mauro, Michael J.
    BLOOD, 2014, 124 (21)
  • [25] Long-Term Safety of Dasatinib in Chinese Chronic Phase Chronic Myeloid Leukemia Patients with Imatinib-Resistance or -Intolerance: Results from a 6-Year Follow-up of a Multicenter Phase II Study
    Huang, Xiaojun
    Jiang, Qian
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    Wang, Jianxiang
    BLOOD, 2016, 128 (22)
  • [26] Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
    Kantarjian, Hagop M.
    Giles, Francis J.
    Bhalla, Kapil N.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Shou, Yaping
    Gallagher, Neil J.
    Blakesley, Rick
    Baccarani, Michele
    Cortes, Jorge
    le Coutre, Philipp D.
    BLOOD, 2011, 117 (04) : 1141 - 1145
  • [27] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
  • [28] Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up.
    Hochhaus, Andreas
    Shah, Neil P.
    Cortes, Jorge E.
    Baccarani, Michele
    Bradley-Garelik, M. Brigid
    Dejardin, David
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [30] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
12345